Neurocrine Biosciences (NASDAQ: NBIX) hosted a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston Wednesday September 9, 2026 at 12:45 p.m. ET, disclosing that CRENESSITY (crinecerfont, a first-in-class oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist for classic congenital adrenal hyperplasia (CAH)) has reached approximately $750 million in quarterly run-rate revenue approximately 12 months after its FDA approval in December 2024 for pediatric patients aged 4 and older and adults with CAH. The company posted its first billion-dollar quarter in Q2 2026 and moved from a single-product company (Ingrezza for tardive dyskinesia) to three commercial products, with underlying Ingrezza volume growth of 17% and 2026 guidance at the $2.85 billion midpoint. CRF is a peptide hormone, and CRENESSITY blocks the CRF1 receptor to reduce excess ACTH secretion and androgen production in CAH — the mechanism replaces high-dose glucocorticoid therapy for many patients. Neurocrine reported zero debt and approximately $500 million in cash.
Neurocrine Biosciences (Nasdaq: NBIX) presented two-year data from CAHtalyst Pediatric showing durable hormone control, reduced glucocorticoid exposure, and improved growth measures in pediatric patients with classic congenital adrenal hyperplasia (CAH), with weight, insulin resistance, and bone-age outcomes also improved at year 2. Separately, Neurocrine announced the first retrospective case series of CRENESSITY (crinecerfont) in patients with classic CAH due to 11β-hydroxylase deficiency, the second-most-common form of CAH after 21-hydroxylase deficiency, accounting for roughly 5% of cases. The 11β-OHD subtype was not previously studied in the crinecerfont trials and is characterized by cortisol deficiency plus excess adrenal androgens and accumulation of 11-deoxycortisol and 11-deoxycorticosterone. Crinecerfont is a small-molecule CRF1 receptor antagonist that dampens the CRH-ACTH peptide signaling axis.
Neurocrine Biosciences announced April 22 two-year data from the Phase 3 CAHtalyst Adult study at AACE 2026 in Las Vegas. CRENESSITY (crinecerfont), a CRF1 receptor antagonist that dampens the CRF-ACTH peptide signaling axis, achieved sustained glucocorticoid dose reductions in adults with classic congenital adrenal hyperplasia: mean daily GC dose decreased from 17.6 to 10.6 mg/m²/day HCe (−38%), and approximately 69% of patients achieved GC doses within the physiologic range while maintaining androgen control. No new safety signals emerged.